Blog

Zappy Zapolin Wants To Change the World with Psychedelics – Podcast Episode #1

Apr 27 • 31 min read

We are so excited to unveil the Psychedelic Invest Podcast to the world. In the first episode, host Bruce Eckfeldt, sits down with Zappy Zapolin to talk about how psychedelics are poised to change the world. New episodes of the podcast will be released weekly. Stay tuned and subscribe to be notified as each episode…

Biomind Labs Doses First Subject in Phase I/IIa Clinical Trial of Its DMT-Based Inhaled Formulation BMND01 for Treatment-Resistant Depression

Apr 26 • 3 min read

Biomind Labs Inc. (NEO: BMND) (OTC: BMNDF) (FSE: 3XI), a leading biotech company focused on developing the next generation of pharmaceuticals to treat patients suffering from neurological and psychiatric disorders by scientifically harnessing the medicinal power of psychedelic molecules, announced today that it has commenced dose administration of the first subject in a Phase I/IIa…

Mindset Pharma Strengthens IP Portfolio with Another New Provisional Patent Application Covering its DMT and 5-MeO-DMT Drug Candidate Compounds

Apr 25 • 3 min read

Mindset Pharma Inc. (CSE: MSET) (FSE: 9DF) (OTCQB: MSSTF), a drug discovery and development company focused on creating optimized and patentable next-generation psychedelic medicines to treat neurological and psychiatric disorders with unmet medical needs, announced today the filing of a new provisional patent application that covers new chemical entities (NCEs) that expand the Company’s next-generation…

PRO: A Deeper Dive Into Cybin (CYBN)

Apr 22 • 1 min read

In our latest episode, Adam Tubero digs into one of the more well-known Psychedelic biotech companies in the industry, Cybin (CYBN). Tune in as we take a closer look at Cybin’s financials, the development of CYB003 – which has the potential to effectively treat major depressive disorder (MDD) and alcohol use disorder (AUD) – and…

Filament Health and Psyence Enter Into Exclusive Licensing Agreement for Natural Psilocybin Products

Apr 22 • 4 min read

Filament Health Corp. (OTCQB: FLHLF | NEO: FH | FSE: 7QS), a clinical-stage natural psychedelic drug development company, and Psyence Group Inc (CSE: PSYG) (OTCQB: PSYGF) (“Psyence”), a life science biotechnology company pioneering the use of natural psilocybin in mental health and well-being, today announced the conclusion of an exclusive licensing agreement with Psyence. Under…

Pages: 123456789101112131415161718192021222324252627282930313233343536373839404142434445464748495051525354555657585960616263646566676869707172737475767778798081828384858687888990919293949596979899100101102103104105106107108109110111112113114115116117118119120121122123124125126127128129130131132133134135136137138139140141142143144145146147148149150151152153154155156157158159160161162163164165166167168169170171172173174175176177178179180181182183184185186187188189190191192193194195196197198199200201202203204205206207208209210211212213214215216217218219220221222223224225226227228229230231232233234235236237238239240241242243244245246247248249250251252253254255256257258259260261262263264265266267268269270271272273274275276277278279280281282283284285286287288289290291292293294295296297298299300301302303304305306307308309310311312313314315316317318319320321322323324325326327328329330331332333334335336337338339340341342343344345346347348349350351352353354355356357358359360361362363364365366367368369370371372373374375376377378379380381382383384385386387388389390391392393394395396397398399400401402403404405406407408409410411412413414415416417418419420421422423424425426427428429430431432433434435436437438439440441442443444445446447448449450451452453454455456457458459460461462463464465466467468469470471472473474475476477478479480481482483484485486487488489490491492493494495496497498499500501502503504505506507508509510511512513514515516517518519520521522523524525526527528529530531532533534535536537538